Markers of Bone Turnover in Gaucher Disease: Modeling the Evolution of Bone Disease von van Dussen, L, Lips, P, Everts, V. E, Bravenboer, N, Jansen, I. D. C, Groener, J. E. M, Maas, M, Blokland, J. A. K, Aerts, J. M. F. G, Hollak, C. E. M

Volltext

‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the lite... von Biegstraaten, M., van Schaik, I. N., Aerts, J. M. F. G., Hollak, C. E. M.

Volltext

Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy von van Dussen, L., Hendriks, E. J., Groener, J. E. M., Boot, R. G., Hollak, C. E. M., Aerts, J. M. F. G.

Volltext

The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statement von Cox, T. M., Aerts, J. M. F. G., Andria, G., Beck, M., Belmatoug, N., Bembi, B., Chertkoff, R., Vom Dahl, S., Elstein, D., Erikson, A., Giralt, M., Heitner, R., Hollak, C., Hrebicek, M., Lewis, S., Mehta, A., Pastores, G. M., Rolfs, A., Sa Miranda, M. C., Zimran, A.

Volltext

The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels von Vedder, A. C., Linthorst, G. E., Breemen, M. J., Groener, J. E. M., Bemelman, F. J., Strijland, A., Mannens, M. M. A. M., Aerts, J. M. F. G., Hollak, C. E. M.

Volltext

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring von Cox, T. M., Aerts, J. M. F. G., Belmatoug, N., Cappellini, M. D., vom Dahl, S., Goldblatt, J., Grabowski, G. A., Hollak, C. E. M., Hwu, P., Maas, M., Martins, A. M., Mistry, P. K., Pastores, G. M., Tylki-Szymanska, A., Yee, J., Weinreb, N.

Volltext

Sustained therapeutic effects of oral miglustat (Zavesca, N‐butyldeoxynojirimycin, OGT 918) in type I Gaucher disease von Elstein, D., Hollak, C., Aerts, J. M. F. G., Weely, S., Maas, M., Cox, T. M., Lachmann, R. H., Hrebicek, M., Platt, F. M., Butters, T. D., Dwek, R. A., Zimran, A.

Volltext

Screening for Fabry disease in high-risk populations: a systematic review von Linthorst, G E, Bouwman, M G, Wijburg, F A, Aerts, J M F G, Poorthuis, B J H M, Hollak, C E M

Volltext

Impact of obesity on taste receptor expression in extra-oral tissues: emphasis on hypothalamus and brainstem von Herrera Moro Chao, D., Argmann, C., Van Eijk, M., Boot, R. G., Ottenhoff, R., Van Roomen, C., Foppen, E., Siljee, J. E., Unmehopa, U. A., Kalsbeek, A., Aerts, J. M. F. G.

Volltext

Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature von de Fost, M., Out, T. A., de Wilde, F. A., Tjin, E. P. M., Pals, S. T., van Oers, M. H. J., Boot, R. G., Aerts, J. F. M. G., Maas, M., vom Dahl, S., Hollak, C. E. M.

Volltext

No Difference in Glycosphingolipid Metabolism and Mitochondrial Function in Glucocorticoid-Induced Insulin Resistance in Healthy Men von Brands, M, van Raalte, D. H, Ferraz, M. João, Sauerwein, H. P, Verhoeven, A. J, Aerts, J. M. F. G, Diamant, M, Serlie, M. J

Volltext

Manifestations of Fabry disease in placental tissue von Vedder, A. C., Strijland, A., Weerman, M. A. vd Bergh, Florquin, S., Aerts, J. M. F. G., Hollak, C. E. M.

Volltext

Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III von Cox-Brinkman, J, van Breemen, M. J, van Maldegem, B. T, Bour, L, Donker, W. E, Hollak, C. E. M, Wijburg, F. A, Aerts, J. M. F. G

Volltext

Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease von Rombach, S.M., Dekker, N., Bouwman, M.G., Linthorst, G.E., Zwinderman, A.H., Wijburg, F.A., Kuiper, S., vd Bergh Weerman, M.A., Groener, J.E.M., Poorthuis, B.J., Hollak, C.E.M., Aerts, J.M.F.G.

Volltext

Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe von Cox-Brinkman, J, Timmermans, R. G. M, Wijburg, F. A, Donker, W. E, van de Ploeg, A. T, Aerts, J. M. F. G, Hollak, C. E. M

Volltext

Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease von de Fost, M, Langeveld, M, Franssen, R, Hutten, B.A, Groener, J.E.M, de Groot, E, Mannens, M.M, Bikker, H, Aerts, J.M.F.G, Kastelein, J.J.P, Hollak, C.E.M

Volltext

Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels von Langeveld, M., Endert, E., Wiersinga, W. M., Aerts, J. M. F. G., Hollak, C. E. M.

Volltext

Vasculopathy in patients with Fabry disease: Current controversies and research directions von Rombach, S.M., Twickler, Th.B., Aerts, J.M.F.G., Linthorst, G.E., Wijburg, F.A., Hollak, C.E.M.

Volltext

Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males von Vedder, A. C, Gerdes, V. E. A, Poorthuis, B. J. H. M, Helmond, M, Trip, M. D, Aerts, J. M. F. G, Hollak, C. E. M

Volltext

Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: Disease spectrum and natural course in attenuated patients von Hollak, C.E.M., de Sonnaville, E.S.V., Cassiman, D., Linthorst, G.E., Groener, J.E., Morava, E., Wevers, R.A., Mannens, M., Aerts, J.M.F.G., Meersseman, W., Akkerman, E., Niezen-Koning, K.E., Mulder, M.F., Visser, G., Wijburg, F.A., Lefeber, D., Poorthuis, B.J.H.M.

Volltext